After winning a Study U.K. Alumni Award, columnist Shalom Lim looks back on the ups and downs of his life with Duchenne ...
Italfarmaco S.p.A. today announced a comprehensive update on the regulatory and clinical advancements for givinostat, the ...
A Boston biotech's decision to pause a Duchenne muscular dystrophy study has resulted in a significant stock drop.
On Tuesday, the FDA accepted for review Capricor Therapeutics Inc’s (NASDAQ:CAPR) Biologics License Application for ...
Researchers, physicians, families and affected patients view Duchenne muscular dystrophy (DMD) as a neuromuscular condition. Children are diagnosed during the first years of life because they have ...
A World of Generosity CureDuchenne’s recent charity partnership with Blizzard Entertainment and multiplayer online ...
The Food and Drug Administration has accepted Capricor Therapeutics' application seeking approval of its cell therapy deramiocel for muscular dystrophy patients and granted it a priority review. The ...
The Food and Drug Administration (FDA) has granted Priority Review to the Biologics License Application (BLA) for deramiocel (CAP-1002) for the treatment ...
PepGen halts its Phase 2 CONNECT2 trial for PGN-EDO51 in DMD to assess 10 mg/kg cohort data, while advancing FREEDOM-DM1 studies in myotonic dystrophy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback